Enhancing adherence, subjective well-being and quality of life in patients with schizophrenia: which role for long-acting risperidone?

ABSTRACT:

Aim

This study evaluated adherence to treatment, quality of life and subjective well-being in patients with psychosis treated with long-acting injectable risperidone. Subjects enrolled were part of a larger study where patients were observed in an adherence to treatment program of the University of Rome Tor Vergata.

Materials and methods

A total of 27 nonadherent patients (21 men, six women; mean age: 36.1 years; range: 23-63 years) were enrolled. Maximum observational period was 30 months.

Results

A total of 12 patients were under treatment for 30 months (44.44%) but only nine had a valid 30-month follow up, while the remaining three patients initially treated at our unit continued long-acting risperidone at their local centre. Reductions of monthly mean values of Sc

SUBMITTER: Niolu C 

PROVIDER: S-EPMC4622121 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature